Jiangsu Wuzhong Pharmaceutical Group Corporation announced a equity round of funding for gross proceeds of CNY 340 million with existing investor JiangSu WuZhong Pharmaceutical Development Co., Ltd. on January 5, 2022. As a part of the round, the registered capital of the company will increase from CNY 400 million to CNY 740 million. Post the capital increase, the investor will retain its 100% stake in the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.85 CNY | +0.31% | +2.07% | +19.83% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.83% | 956M | |
+51.82% | 797B | |
+40.45% | 628B | |
+16.95% | 323B | |
+9.49% | 300B | |
+17.25% | 244B | |
+0.41% | 223B | |
+10.22% | 214B | |
+5.30% | 163B | |
-6.29% | 153B |
- Stock Market
- Equities
- 600200 Stock
- News JiangSu WuZhong Pharmaceutical Development Co., Ltd.
- Jiangsu Wuzhong Pharmaceutical Group Corporation announced that it expects to receive CNY 340 million in funding from JiangSu WuZhong Pharmaceutical Development Co., Ltd.